Biography
Dr. Peter Scott is Professor of Radiology, Pharmacology and Medicinal Chemistry at the University of Michigan. He is the Division Director of Nuclear Medicine and Director of the Department of Radiology’s Cyclotron and Radiochemistry facility.
Dr. Scott obtained his undergraduate degree in medicinal chemistry from Loughborough University (2001) and his PhD in organic chemistry from Durham University (2005), both in the UK. He then moved to the US for postdoctoral research in organometallic chemistry at SUNY Buffalo (2005-2006), and PET radiochemistry at the University of Michigan (2006-2007, under Prof. Michael Kilbourn). Peter worked for Siemens Molecular Imaging for a few years after his post doc where he led radiochemistry at the Technology Center in Los Angeles. He started his independent faculty career at the University of Michigan in 2009.
Dr. Scott's group is involved in all aspects of the Radiopharmaceutical Sciences including
- developing new methods for radiolabeling bioactive molecules
- design and synthesis of new radiotracers for PET imaging of CNS disorders such as Alzheimer's disease
- cGMP radiopharmaceutical manufacture
- adapting new technology (e.g. artificial intelligence, internet of things) to imagine the radiochemistry laboratory of the future.
The goals of his lab are to use PET radiotracers to improve our understanding of disease mechanisms and, ultimately, employ them as companion diagnostics to support therapeutic development. Dr. Scott has published hundreds of papers and conference abstracts, over 30 book chapters, edited several books, and he is listed as an inventor on multiple patents. His laboratory is funded by the National Institutes of Health, and has multiple collaborations with academic institutions, biotech and pharma companies all over the world. He has received numerous awards for his research including, most recently, the 2023 Sam Gambhir Trailblazer Award from SNMMI.
Areas of Interest
- New radiochemistry methodology
- Development and translation of radiopharmaceuticals for PET imaging and radiotherapy
- cGMP radiopharmaceutical manufacture
- Theranostics
- Artificial intelligence and machine learning